| Document |
Document Title |
|
WO/2021/207453A1 |
The present description relates to compounds of Formula (I), forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
|
|
WO/2021/204857A1 |
Compounds of the formula (I): Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2021/204800A1 |
A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammator...
|
|
WO/2021/204666A1 |
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X and Y represent radicals such as hydrogen, alkyl and halogen. Z1 and Z2 represent radicals such as alkyl, cycloalkyl and ...
|
|
WO/2021/204669A1 |
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...
|
|
WO/2021/205290A1 |
The invention relates to compounds of formula (I) wherein R1 and R2 are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amou...
|
|
WO/2021/204159A1 |
The present disclosure provides compounds represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, V, Q, T, n, p, q, r and s are as defined as set forth in the specification. The present disclosu...
|
|
WO/2021/204801A1 |
A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammator...
|
|
WO/2021/207302A1 |
The present disclosure provides compounds of formula (I) and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
|
|
WO/2021/203190A1 |
Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inh...
|
|
WO/2021/207554A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/204822A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2021/207172A1 |
Bifunctional compounds, which find utility as modulators of Kirsten ras sarcoma protein (KRas or KRAS), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that bin...
|
|
WO/2021/203673A1 |
The present application provides a nitrogen containing compound, an organic electroluminescent device using same, and an electronic device. A chemical structure of an organic compound in the present invention comprises a carbazole ring. ...
|
|
WO/2021/204706A1 |
The present invention relates to a compound of Formula (I), wherein Q, R1 and R3, X and n are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compound...
|
|
WO/2021/204856A1 |
The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction,...
|
|
WO/2021/201036A1 |
The present invention provides a target protein degradation inducing compound which is a bifunctional compound having, at one terminal, a portion that binds to VHL which is a substrate recognition protein of a ubiquitin ligase complex an...
|
|
WO/2021/198188A1 |
The present invention relates to a new class of quinazolinone derivatives of formula (I) and their uses for treating cancer. The invention further relates to pharmaceutical compositions comprising compounds of formula (I). (I)
|
|
WO/2021/203028A1 |
7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).
|
|
WO/2021/198191A1 |
The present invention relates to a new class of quinazolinone derivatives of formula (I), and their uses for treating a cancer. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I).
|
|
WO/2021/202600A1 |
Disclosed are small molecule inhibitors of influenza HA, and methods of using them to treat or prevent HA-mediated diseases and conditions.
|
|
WO/2021/203023A1 |
Indole derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).
|
|
WO/2021/202781A1 |
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for pre...
|
|
WO/2021/198956A1 |
Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
|
|
WO/2021/197486A1 |
A novel spiro compound and an application thereof in a drug, in particular, use thereof as a drug for treating and/or preventing hepatitis B. Specifically, the present invention relates to a compound represented by formula (I) or a stere...
|
|
WO/2021/197499A1 |
Disclosed is a class of octahydropyrazinodiazanaphthyridine dione compounds, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/194879A1 |
Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to ...
|
|
WO/2021/191390A1 |
Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them includ...
|
|
WO/2021/191384A1 |
Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treati...
|
|
WO/2021/195400A1 |
A method for treating a viral infection of a mammalian subject that comprises administering a virus- inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide deri...
|
|
WO/2021/193897A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of th...
|
|
WO/2021/195183A1 |
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such...
|
|
WO/2021/193790A1 |
The present invention provides a compound which has a serotonin 5-HT2A receptor inverse agonist effect, a pharmaceutically acceptable salt thereof, and a composition which is for serotonin 5-HT2A receptor inverse agonism and which contai...
|
|
WO/2021/190727A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
|
|
WO/2021/191202A1 |
The invention relates to a new process for preparing compounds of the formula (I) and pharmaceutically acceptable salts thereof, which act as ferroportin inhibitors being suitable for the use as medicaments in the prophylaxis and/or trea...
|
|
WO/2021/190337A1 |
Disclosed are a salt form and a crystal form of a compound as an SMO inhibitor, and specifically discloses crystal form I of compound 1. The XRPD spectrum of crystal form I of compound 1 has diffraction peaks at 2θ=3.7, 7.4, 10.2, 12.0,...
|
|
WO/2021/195211A1 |
The present invention relates to the use of a quinoline compound, or a pharmaceutically acceptable salt thereof, for treatment of ARDS, viral infections, and other diseases, disorders, and conditions such as those described herein.
|
|
WO/2021/187605A1 |
The present invention provides a compound useful as an active ingredient of a pharmaceutical composition for prophylaxis or treatment of premature ejaculation. Provided is a compound represented by formula (I) below [in the formula, A is...
|
|
WO/2021/185829A1 |
The invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/187886A1 |
The present invention relates to a novel compound useful as an agent for treatment or prophylaxis of various metabolic diseases such as obesity or diabetes and hyperlipidemia, by means of excellent GLP-1 agonist activity and an excellent...
|
|
WO/2021/188944A1 |
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be u...
|
|
WO/2021/184339A1 |
Provided herein are the oxazolidinone compound of Formula (I) and pharmaceutically acceptable salts thereof. It also relates to compositions containing the compound of Formula (I). Provided herein also are methods for inhibiting growth o...
|
|
WO/2021/188620A1 |
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sa...
|
|
WO/2021/186406A1 |
The present invention provides a co-crystal of sulfentrazone and a triazinone herbicide and process for preparation thereof. The present invention also provides an agrochemical composition comprising said co-crystal and process of prepar...
|
|
WO/2021/188769A1 |
Compounds that inhibit HIF-2a, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse arr...
|
|
WO/2021/185806A1 |
The present invention relates to the crystal forms of methyl(2R*,4R *)-4-[[(5S)-3-(3,5-difluorophenyl)-5-vinyl-4H-isoxazole-5- carbonyl]amino]tetrahydrofuran-2-carboxylate (I) existing in the form of two stereoisomers: Methyl(2R,4R)-4-[[...
|
|
WO/2021/143729A9 |
The present invention relates to a compound, a composition and a functional molecule with a multi-target inhibiting effect and the use thereof. The compound is a compound having a structure represented by formula (I). Specifically, K is ...
|
|
WO/2021/185291A1 |
A proteolysis targeting chimera (PROTAC), and an application thereof in preparation of a drug for treating a related disease. Specifically disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt ther...
|
|
WO/2021/187486A1 |
The present invention relates to the compound represented in formula (1) or a pharmaceutically acceptable salt thereof (in the formula, Q1 represents a halogen, Q2 represents a hydrogen, etc., X, Y and Z represent a nitrogen atom or an o...
|
|
WO/2021/185878A1 |
Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the TAAR1 agonist 5-ethyl-4-methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3- carboxamide. Also described are pharmaceutical compositions ...
|
